VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine  for the Prevention of Alzheimer's Disease. 
​​YM7555 – Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU

VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of Alzheimer’s Disease. The vaccine is a gene-based (DNA)  vaccine, which targets ABeta and TAU and is in development for prevention of Alzheimer's disease (AD). Unlike a traditional vaccine for AD, the DNA vaccine does not contain ABeta or Tau peptide itself but instead contains a piece of the gene coding for the Abeta and Tau protein. Once in the body, the vaccine stimulates an immune response resulting in antibodies that bind to and significantly reduce ABeta and Tau.  ABeta and TAU accumulation in the brain has been found in all patients having AD.  Research has shown that a unique property of this vaccine is that it is a Th2 immune response and does not elicit an inflammatory response in the brain, which is critical for a successful vaccine. The YN7555 vaccine was licensed from Dr. Yoh Matsumoto from the Tokyo Metropolitan Institute of Medical Science and Immunotherapy Development Inc. 
In addition to the YM7555 vaccine VITRUVIAN has also licensed from Dr. Matsumoto YM3711, which is a DNA vaccine targeting only ABeta and has IND information. VITRUVIAN has also licensed vaccines specific for only TAU.  In addition VITURVIAN has developed its own proprietary ABeta vaccine as well as a new delivery system for DNA vaccines. Due to the necessary involvement of both ABeta and TAU in all cases of AD, the focus is on YM7555, which targets both ABeta and TAU. P
The AD DNA Vaccine YM7555 has shown a major reduction in accumulation of ABeta and TAU and complete inhibition of phosphorylated TAU, which is the most toxic TAU form, in treated transgenic mice, which carry an AD-related gene  YM7555 elicits a strong immune response in the transgenic mice and rabbits and response in primates is in development.  The YM3711, which only targeted ABeta, showed a very strong immune response in primates, (ARC Journal of Immunology and Vaccines, Volume 2, Issue 1, 2017, PP9-15). The goal is to complete an IND and implement Phase 1b/2a clinical trials of YM7555 in 2018-2019.


VITRUVIAN is also focused on a possible Alzheimer’s Disease Biomarker which is in development as a Blood Test for early stage Alzheimer's Disease. Biomarkers are unique molecules, which permit identification of different diseases. This proprietary Alzheimer's Disease Biomarker could serve as the basis for a Diagnostic Blood Test which could help identify candidates for the Alzheimer's Disease Therapeutic Vaccine. In a study comparing the AD Biomarker levels in Serum from early stage AD to Serum of non-AD, the AD Biomarker was increased 2.5 fold in the Serum of early stage AD. Expanded studies using serum from early stage AD patients is in progress.
In the United States alone, Alzheimer's disease currently affects 5.4 million people and their families. It is the most common form of dementia and the fifth leading cause of death for individuals 65 years and older. The Alzheimer's Association estimates that the disease results in $250 billion dollars of healthcare costs in the United States each year

Alzheimer's Facts & Figures

  • Alzheimer's Disease is the 6th leading cause of death in the United States. 

  • More than 5 Million Americans are living with Alzheimer's.  By 2050 this number could rise as high as 16 Million.

  • Every 66 Seconds someone in the United States develops the disease.

  • In 2017, Alzheimer's and other dementias will cost the nation $259 Billion. By 2050, these costs cound rise as high as $1.1 Trillion
  • Since 2000, deaths from heart disease decreased by 14%, while deaths from Alzheimer's disease have increased by 89%